title: Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo.
abstract: Multidrug resistance (MDR) is a major impediment to cancer treatment. A promising strategy for treating MDR is the joint delivery of combined anticancer agents to tumor cells in a single nanocarrier. Here, for the first time, Resveratrol (Res) was co-encapsulated with paclitaxel (PTX) in a PEGylated liposome to construct a carrier-delivered form of combination therapy for drug-resistant tumors. The composite liposome had an average diameter of 50 nm with encapsulated efficiencies of above 50%. The studies demonstrated that the composite liposome could generate potent cytotoxicity against the drug-resistant MCF-7/Adr tumor cells in vitro and enhance the bioavailability and the tumor-retention of the drugs in vivo. Moreover, systemic therapy with the composite liposome effectively inhibited drug-resistant tumor in mice (p < 0.01), without any notable increase in the toxicity. These results suggested that the co-delivery of Res and a cytotoxic agent in a nanocarrier may potentially improve the treatment of drug-resistant tumors.
authors.affiliation: Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Meng
authors.affiliation: South China Normal University, Guangdong, China.
authors.forename: Fangqin
authors.initials: F
authors.lastname: Guo
authors.affiliation: Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union College, Beijing, China.
authors.forename: Haiyan
authors.initials: H
authors.lastname: Xu
authors.affiliation: Institute of Biophysics, Beijing, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Liang
authors.affiliation: Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing, China.
authors.forename: Chen
authors.initials: C
authors.lastname: Wang
authors.affiliation: Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union College, Beijing, China.
authors.forename: Xian-Da
authors.initials: XD
authors.lastname: Yang
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000008:administration & dosage; D018432:Drug Resistance, Multiple / Q000187:drug effects*; D005260:Female; D008081:Liposomes / Q000008:administration & dosage*; D008807:Mice, Inbred BALB C; D017239:Paclitaxel / Q000008:administration & dosage* / Q000494:pharmacology; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage* / Q000494:pharmacology; D016896:Treatment Outcome; D050257:Tubulin Modulators
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D008081:Liposomes; D013267:Stilbenes; D050257:Tubulin Modulators; D017239:Paclitaxel; D000077185:Resveratrol